- Home
- ROIV vs RPRX Comparison
ROIV vs RPRX Comparison
Compare ROIV & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | RPRX |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 25.9B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ROIV | RPRX |
|---|---|---|
| Price | $35.43 | $56.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | $48.08 | ★ $65.38 |
| AVG Volume (30 Days) | ★ 6.0M | 2.5M |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 1.67% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | $8,260,000.00 | ★ $2,378,193,000.00 |
| Revenue This Year | $530.75 | $47.38 |
| Revenue Next Year | $685.92 | $8.97 |
| P/E Ratio | ★ N/A | $79.17 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $15.99 | $35.23 |
| 52 Week High | $42.50 | $64.38 |
Technical Indicators
Market Signals| Indicator | ROIV | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 39.99 |
| Support Level | $33.15 | $56.36 |
| Resistance Level | $35.70 | $58.84 |
| Average True Range (ATR) | 1.14 | 1.08 |
| MACD | -0.34 | -0.14 |
| Stochastic Oscillator | 35.90 | 45.13 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.